Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces that Theresa Heggie has resigned from her position as Member of the Board of Directors, effective immediately.
Theresa Heggie will take up a not yet published executive position that is not possible to combine with a role as a Member of the Board of Sobi.
“On behalf of the Board of Directors, I would like to express my appreciation for her time and contribution,” says Håkan Björklund, Chairman of the Board. “We wish her all the best for the future.”
As a result of Theresa Heggie’s resignation from the Board of Directors, Sobi’s nomination committee has informed Sobi that the nomination committee will amend its proposal to Sobi’s annual general meeting 2017 such that the number of ordinary board members shall be six instead of seven and that Theresa Heggie will not be proposed for re-election.
Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016 Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.
|For more information please contact
|Morten Grøn, Vice President, Head of Communications
||Jörgen Winroth, Vice President, Head of Investor Relations
|T: + 45 25 56 47 81
||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135